Jiangsu Hengrui Pharma has chalked up a first-in-class approval for retlirafusp alfa, a bifunctional drug that targets PD-L1 ...
PD-1 and PD-L1 inhibitors are types of immune checkpoint inhibitors, which are immunotherapy medications for treating cancer. Immunotherapy helps the immune system find and kill cancer cells. Some ...
Tracon Pharmaceuticals Inc. is shuttering all development of its subcutaneous PD-L1 antibody, envafolimab, after the pivotal trial failed to meet the primary endpoint in soft tissue sarcoma.
First-line treatment with ivonescimab led to a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with pembrolizumab (Keytruda) in patients ...
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced that in a recent meeting the U.S. Food and Drug Administration (FDA) concurred with the Company’s approach to ...
More than two years after an initial FDA approval in melanoma, Bristol Myers Squibb is moving its PD-1/LAG-3 combo Opdualag into registrational testing in one of the most important oncology disease ...
The days of broad approvals for PD-1 inhibitors in stomach and esophageal cancers appear to be numbered. A group of external advisers to the FDA voted 10-2 that the use of PD-1 inhibitors in ...
BioWorld - Thursday, July 18, 2024 See today's BioWorld Asia See today's BioWorld Home » Tracon quits work on anti-PD-L1 envafolimab after phase III flop Subscribe to BioWorld™ news services See ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback